Meet our 2021 Employee Champions. We recognize individuals who strive to advance science and support innovation so that patients around the world can get the medicines and treatments they need. This year’s recipients have demonstrated commitment and resiliency that goes above and beyond expectations.
President of Neuroscience | Johnson & Johnson
Pearl has long been an advocate in the mental health space, reducing the stigma surrounding mental health issues.She has also taken a hands-on approach to supporting underserved populations and walked alongside street medicine physicians on Skid Row in Los Angeles, and her work has fostered compassion and understanding in the community.
Global Head of Scientific Engagement | Novartis
Ian collaborates with the Novartis US Public Affairs team, allowing the company to demonstrate its work and commitment to advancing unmet medical needs for patients across the globe. Ian and his team have met with key members of state legislatures across the United States.
Associate Director, D&I | Novartis
Vanessa, in partnership with her colleague, Dr. Anderson, served as the U.S. D&I leads for the Employee Resource Group (ERG) Capitol Hill Fly-In. They worked to produce content, align with ERG associates for the opportunity and partnered with Public Affairs to execute the initiative. The Fly-in provided Novartis associates who participate in ERGs with an
U.S. Head of D&I, Strategy and Operations | Novartis
Dr. Anderson, in partnership with her colleague, Vanessa Adams, served as the U.S. D&I leads for the Employee Resource Group (ERG) Capitol Hill Fly-In. They worked to produce content, align with ERG associates for the opportunity and partnered with Public Affairs to execute the initiative. The Fly-in provided Novartis associates who participate in ERGs with
Commercial Lead for Digital Therapeutics | Otsuka America Pharmaceutical, Inc.
With years of experience in both pharmaceuticals and digital medicine, Rohit is driving Otsuka’s launch strategy to bring prescription digital therapeutics to patients suffering from serious mental illness. His work has propelled Otsuka as a driver of legislation around creating a benefit category and reimbursement paradigm for PDTs.
Senior Director, Development Team Leader of Global Clinical Development | Otsuka
Saloni’s work brought the first-ever approved treatment to address symptoms of agitation associated with dementia due to Alzheimer’s disease. She has also engaged with members of Congress and administration staff to help drive awareness of the disease. Additionally, she has advocated for policy changes that are reflective of the evolving treatment landscape.
Vice President, Global Data, Platforms & Partnerships | Janssen (Pharmaceutical Companies of Johnson & Johnson)
Over the years, Dr. Chureen Carter has demonstrated her commitment to supporting and mentoring rising scientists. In her work building alliances that support evidence generation, Dr. Carter puts patients first, ensuring stakeholders understand the full value of the medicines they need. She has an exceptional ability to build bridges, whether with partners outside the organization
Director of U.S. Pricing Analytics | Merck
A self-described “number monkey,” Doug’s work in data modeling has been an essential component of Merck’s legislative strategy. Doug is committed to ensuring the government affairs team is always equipped with data to guide and advance their advocacy efforts. His recent work on drug pricing reform echoes his ability to supply complex guidance in a
Senior Director in the Biomarker Center of Excellence, R&D | Biogen
In 2020, Dr. Dent was a key voice in discussing the importance of biomarkers for Alzheimer’s disease with members of Congress. She participated in Capitol Hill briefings and attended multiple meetings with legislators to explain the issue. She is a powerful advocate for pioneering innovation and continues to be a trusted advisor and partner to
Associate Clinical Scientist | Bristol Myers Squibb
As a specialist in cell therapy, Victoria has played a vital role in engaging policymakers at every level of government including state and federal “fly-ins” hosted by PhRMA. BMS’s Policy, Government Affairs, and Advocacy team is continually impressed by her thoughtful approach to educating and advocating for medical innovation, like CAR T.